Nicotinamide Riboside Supplementation Improves Alzheimer's Biomarkers in Subjective Cognitive Decline and Mild Cognitive Impairment: Clinical Findings
Objectives
To test the safety and efficacy of oral NR supplementation on cognition and Alzheimer's disease (AD) blood biomarkers in older adults with subjective cognitive decline and mild cognitive impairment (MCI).
Journal
Alzheimer's & Dementia: Translational Research & Clinical Interventions
Key Outcomes
- NR supplementation had no impact on cognition.
- NR resulted in a 7% reduction in plasma pTau217 concentrations, a biomarker for AD, while placebo resulted in an 18% increase..
Duration
8 weeks
Dose
1000 mg
Study Design
Randomized, double-blind, placebo-controlled, crossover study in 46 older adults with subjective cognitive decline and mild cognitive impairment (MCI)